Novartis' Del-Desiran Misses Primary Endpoint in Phase 3 HARBOR Trial for Myotonic Dystrophy Type 1

Novartis (NYSE: NVS) said Tuesday that del-desiran, its antibody oligonucleotide conjugate (AOC) for myotonic dystrophy type 1 (DM1), missed the primary endpoint in the global Phase 3 HARBOR study. The drug did not deliver a statistically significant improvement over placebo on video hand opening time (vHOT), a measure of hand myotonia, in a disease that still has no approved therapy.

The numbers

HARBOR randomized approximately 150 adults with DM1 to del-desiran or placebo, dosed every eight weeks over 54 weeks:

• Primary endpoint (vHOT): missed, no statistically significant improvement versus placebo
• Secondary and exploratory endpoints: Novartis reported “evidence of clinical activity” but disclosed no figures, saying it will analyze the full dataset
• Safety: generally consistent with previously reported data

Novartis did not release efficacy numbers, a contrast with the detailed data it has shared for its other AOC programs. The company said it will engage with health authorities to determine the most appropriate development path for del-desiran.

Why it matters

Del-desiran is one of three AOCs Novartis picked up in its $12 billion acquisition of Avidity Biosciences, which closed in late 2025. The therapy pairs a transferrin receptor 1 (TfR1)-targeting antibody with an siRNA payload that degrades the toxic DMPK messenger RNA behind DM1, and it carried Orphan Drug, Fast Track, and Breakthrough Therapy designations. HARBOR was the first test of whether the AOC platform could translate biomarker wins into functional benefit in a rare muscle disease.

The miss is Novartis’ second Phase 3 failure in five days. On Friday, the company said pelacarsen failed to reduce cardiovascular risk in the roughly 8,300-patient Lp(a)HORIZON study, a result that also raises questions for other Lp(a) programs from Eli Lilly and Amgen. Shares fell about 14% Tuesday to $137.70 from Friday’s $159.99 close, and were little changed Wednesday around $137.50.

The read-through cuts both ways for the AOC field. Novartis is still advancing del-zota in Duchenne muscular dystrophy (exon 44), which carries FDA priority review, and del-brax in facioscapulohumeral muscular dystrophy after positive Phase 1/2 biomarker data. But the HARBOR miss opens the door for Dyne Therapeutics, whose antisense candidate z-basivarsen is now being called the frontrunner in DM1 by analysts.

What to watch

Novartis will present the full HARBOR dataset and decide whether to continue del-desiran, while Dyne’s Phase 1/2 z-basivarsen topline in DM1 is expected early next year. For background on the AOC platform and its FSHD readout, see our coverage of Novartis’ del-brax program. The full study details are on ClinicalTrials.gov, and Novartis’ statement is available on its media releases page.

What It Means for the Trade

The 14% drop to $137.70 reflects two failures priced together: pelacarsen’s Lp(a)HORIZON miss on Friday and HARBOR on Tuesday. Separately, each is survivable for a company of Novartis’s diversification; together they form a week that raises the core question about the $12 billion Avidity acquisition — whether antibody-oligonucleotide conjugates convert biomarker wins into functional endpoints. HARBOR was the first registrational test of that question, and the answer was no on vHOT. Novartis releasing no efficacy figures at all, in contrast to the detailed sharing on its other AOC programs, is the tell that the internals do not help the story.

The concentration math: an approximately 150-patient, 54-week trial missing its primary on hand myotonia is a genuinely ambiguous result — vHOT is one of the noisier functional instruments in neuromuscular disease, and DM1 heterogeneity is notorious. “Evidence of clinical activity” without numbers could mean a near-miss worth rescuing or a flatline. The full dataset presentation will be decisive for del-desiran, and possibly for the platform’s perceived value.

Mechanism and Market Context

The AOC concept remains mechanistically sound: a TfR1-targeting antibody carries an siRNA across the muscle membrane — the delivery problem that has stalled oligonucleotide muscle programs for a decade — to degrade the toxic DMPK mRNA driving DM1. The science cleared the hard part (delivery and target engagement); what failed was the conversion of molecular effect into a functional endpoint at the dose and duration tested. That failure pattern — biomarker-positive, function-negative — is the AOC field’s known achilles heel, and HARBOR now becomes the reference case.

The competitive reshuffle is the second-order story. Dyne Therapeutics’ z-basivarsen, an antisense approach to the same DMPK target, inherits the frontrunner label in DM1 by default, with Phase 1/2 topline expected early next year. A category where the leader just missed its Phase 3 is a fragile leadership position — Dyne’s readout will be judged against a bar that just moved, and DM1 now has a cautionary tale priced into every program’s multiple.

Risks and What Could Go Wrong

1. Program ambiguity. If the full HARBOR data shows a genuine signal in a subgroup or secondary measure, del-desiran continues at additional cost; if it is flat, a $12 billion deal’s lead asset is written down.
2. Platform contagion. Del-zota’s priority review in Duchenne exon 44 and del-brax’s FSHD program are different diseases, but AOC sentiment is one trade — HARBOR softens all of them.
3. Dyne as the read-through. A z-basivarsen miss next year would suggest the DM1 endpoint problem is unsolved at the class level, not a del-desiran-specific issue. For NVS holders, this is a two-in-a-week bad stretch in a diversified giant, absorbable. For the neuromuscular gene-medicine trade, it is a repricing event.